{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-26-000059","form_type":"8-K/A","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2026-09-03T20:39:01+00:00","discovered_at":"2026-09-03T20:42:24.522465+00:00","generated_at":"2026-09-03T20:42:34.203185+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MacroGenics restates pro forma to treat CDMO sale as discontinued ops; net cash $110.8M","bullets":["CDMO sale to Bora closed 6/30/26; gross proceeds $122.5M, net cash $110.8M after $8.8M costs; up to $5M contingent.","Pro forma continuing ops net loss: Q1'26 $41.3M vs $36.8M hist; FY25 $91.2M vs $74.6M; FY24 $68.6M vs $67.0M; FY23 $11.3M vs $9.1M.","CDMO revenue eliminated from continuing ops: Q1'26 $14.1M, FY25 $52.6M, FY24 $13.1M, FY23 $9.8M.","Company now focuses on R&D pipeline; CDMO results reported as discontinued operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-26-000059","json":"https://secwatch.observer/filing/0001125345-26-000059.json","markdown":"https://secwatch.observer/filing/0001125345-26-000059.md","text":"https://secwatch.observer/filing/0001125345-26-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000059/0001125345-26-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000059/mgnx-20260903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T20:42:34.203185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}